Experimental immunomodulatory therapy of inflammatory bowel disease

Netherlands Journal of Medicine

Volumn 53, Issue 6, 1998, Pages

  Schreiber, S ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b Tabea Centre for Inflammatory Bowel Disease   (Germany)

Author keywords

Crohn's disease; Immunomodulation; Inflammatory bowel disease; Therapy; Ulcerative colitis

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CONFERENCE PAPER; CROHN DISEASE; DISEASE CLASSIFICATION; DRUG DESIGN; ENTERITIS; HUMAN; IMMUNOMODULATION; ULCERATIVE COLITIS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR ADHESION MOLECULE-1; INTESTINAL MUCOSA; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; RNA, MESSENGER;

EID: 0031766641     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00120-X     Document Type: Conference Paper

References (55)

1. Saverymuttu S.H., Peters A.M., Lavender J.P., Pepys M.B., Hodgson H.J., Chadwick V.S. Quantitative fecal indium 111-labeled leucocyte excretion in the assessment of disease activity in Crohn's disease. Gastroenterology. 85:1983;1333-1339.
2. Saverymuttu S.H., Peters A.M., Lavender J.P., Chadwick V.S., Lavender J.P. In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut. 26:1985;378-383.
3. Schoelmerich J., Schmidt E., Schumichen C., Billmann P., Schmidt H., Gerok W. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99 m hexamethyl propylene amine oxine as leukocyte label. Gastroenterology. 95:1988;1287-1293.
4. Grisham M.B., Granger D.N. Neutrophil mediated muscosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 33:1988;6S-15S.
5. Faden H., Rossi T.M. Chemiluminescent response of neutrophiles from patients with inflammatory bowel disease. Dig Dis Sci. 30:1985;139-142.
6. Anton P.A., Targan S.R., Shanahan F. Increased neutrophil receptors for and response to the pro-inflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology. 97:1989;20-28.
7. Kelleher D., Feighery C., Weir D.G. Chemiluminescence by polymorphonuclear leucocyte subpopulations in chronic inflammatory bowel disease. Influence of the cell separation procedure. Digestion. 45:1990;158-165.
8. Baldassano R.N., Schreiber S., Johnston R.B., Muraki T., MacDermott R.P. Monocytes of patients with Crohn's disease are primed for accentuated release of toxic oxygen metabolites: possible role for endotoxin. Gastroenterology. 105:1993;60-66.
9. Griga T., Tromm A., Schwegler U., May B. Enhanced superoxide anion release of normal neutrophil granulocytes primed with sera of patients with inactive inflammatory bowel disease. Z Gastroentrol. 33:1995;345-348.
10. Andus T., Gross V., Caesar I.et al. PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci. 38:1993;1638-1644.
11. Adeyemi E.O., Hodgson H.J. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol. 27:1992;139-142.
12. Duchmann R., Kaiser I., Herrmann E., Mayet W., Ewe K., Meier zum Büschenfelde K.H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 102:1995;448-455.
13. Mahida Y.R., Wu K., Jewell D.P. Enhanced production of interleukin 1β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut. 30:1989;835-838.
14. Ligumsky M., Simon P.L., Karmeli F., Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut. 31:1990;686-689.
15. Brynskov J., Tvede N., Andersen C.B., Vilien M. Increased concentrations of interleukin 1β, interleukin 2, and soluble interleukin-2 receptors in endoscopic mucosal biopsy specimens with active inflammatory bowel disease. Gut. 33:1992;55-58.
16. Pullman W.E., Elsbury S., Masanobu K., Hapel A.J., Doe W.F. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology. 102:1992;529-537.
17. Nikolaus S., Bauditz J.U., Raedler A., Lochs H., Schreiber S., Enhanced secretion of pro-inflammatory cytokines by IBD polymorphonuclear neutrophils and regulation by interleukin-10. Gut (1997) in press.
18. Reinecker H.-C., Steffen M., Witthoeft T.et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's Disease. Clin Exp Immunol. 94:1993;174-181.
19. Stevens C., Walz G., Singaram C.et al. Tumor necrosis factor-a, interleukin-1β and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci. 37:1992;818-826.
20. Isaacs K.L., Sartor R.B., Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 103:1992;1587-1595.
21. Woywodt A., Neustock P., Kruse A.et al. Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease. Eur Cytokine Netw. 5:1994;387-395.
22. Kern J.A., Lamb R.J., Reed J.C.et al. Dexamethasone inhibition of interleukin-1-beta production by human monocytes. J Clin Invest. 81:1988;237-244.
23. Derkx B., Taminiau J., Radema S.et al. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet. 342:1993;173-174.
24. Van Dullemen H.M., van Deventer S.J.H., Hommes D.W.et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2). Gastroenterology. 109:1995;129-135.
25. Targan S.R., Hanauer S.B., van Deventer S.J.H.et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. New Engl J Med. 337:1997;1029-1035.
26. Lieberman B.Y., Fiocchi C., Youngman K.R., Sapatnekar W.K., Proffitt M.R. Interferon gamma production by human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease. Dig Dis Sci. 33:1988;1297-1304.
27. Essner R., Rhoades K., McBride W.H., Morton D.L., Esconomou J.S. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol. 142:1989;3857-3861.
28. Donnelly R.P., Fenton M.J., Finbloom D.S., Gerrard T.L. Differential regulation of IL-1 production in human monocytes by IFN-g and IL-4. J Immunol. 145:1990;569-575.
29. Vannier E., Miller L.C., Dinarello C.A. Coordinated anti-inflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA. 89:1992;4076-4080.
30. Karttunnen R., Breese E.J., Walker-Smith J.A., MacDonald T.T. Decreased mucosal interleukin-4 production in gut inflammation. J Clin Pathol. 47:1994;1015-1018.
31. West G.A., Matsuura T., Levine A.D., Klein J.S., Fiocchi C. Interleukin 4 in inflammatory bowel and mucosal immune reactivity. Gastroenterology. 110:1997;1683-1695.
32. Desreumaux P., Brandt E., Gambiez L.et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology. 113:1997;118-126.
33. Mosmann T.R. Regulation of immune responses by T cells with different cytokine secretion profiles: Role of a new cytokine, cytokine synthesis inhibitory factor (IL-10). Int Arch Allergy Appl Immunol. 94:1991;110-115.
34. De Waal Malefyt R., Yssel H., Roncarolo M.-G., Spits H., de Vries J.E. Interleukin 10. Curr Opin Immunol. 4:1992;314-322.
35. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 147:1991;3815-3822.
36. Ralph P., Nakoinz I., Sampson-Johannes A.et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol. 148:1992;808-814.
37. Oswald I.P., Gazzinelli R.T., Sher A., James S.L. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol. 148:1992;3578-3582.
38. Fiorentino D.F., Zlotnik A., Viera P.et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 146:1991;3444-3451.
39. De Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 174:1991;1209-1220.
40. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 170:1989;2081-2085.
41. Schreiber S., Heinig T., Thiele H.G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 108:1995;1434-1444.
42. Van Deventer S.J.H., Elson C.O. Fedorak RN for the Crohn's disease study group. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology. 113:1997;383-390.
43. Fedorak R.N., Gangl A., Elson C.O.et al. Tilg H and the IL-10 study group. Safety, tolerance and activity of multiple doses of subcutaneous recombinant human interleukin-10 (rHulL-10) in patients with mild to moderate Crohn's disease. Gut. 41(S3):1997;A16.
44. Herfarth H.H., Mohanty S.P., Rath H.C., Tonkonogy S., Sartor R.B. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut. 39:1996;836-845.
45. Lenardo M.J., Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 58:1989;227-229.
46. Baldwin A.S. The NF-KB and I-KB proteins: New discoveries and insights. Annu Rev Immunol. 14:1996;649-681.
47. Shakhov A.N., Collart M.A., Vassali P., Nedospasov S.A., Jongeneel C.V. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med. 171:1990;35-47.
48. Kunsch C., Rosen C.A. NF-kappa B subunit specific regulation in the interleukin-8 promoter. Mol Cell Biol. 13:1993;6137-6146.
49. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of lkB-a proteolysis by site-specific signal induced phosphorylation. Science. 267:1995;1485-1487.
50. Ledebur H.C., Parks T.P. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem. 270:1995;933-943.
51. Ziegler-Heitbrock H.W., Stemsdorf T., Liese J.et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol. 151:1993;6986-6993.
52. Neurath M.F., Petterson S., Meyer zum Büschenfelde K.H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Medicine. 2:1996;998-1004.
53. Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut (1997) in press.
54. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Jr. Role of transcriptional activation by lkB in mediation of immunosuppression by glucocorticoids. Science. 270:1995;283-286.
55. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NFκB activity through induction of lkB synthesis. Science. 270:1995;286-290.